OTCMKTS:TRLPF - Acerus Pharmaceuticals Stock Price, Forecast & News

Add

Compare

Today's Range N/A

50-Day Range

$0.05

MA: $0.10▼

$0.12

52-Week Range N/A

Volume10,600 shs

Average Volume1,652 shs

Market Capitalization$23.28 million

P/E RatioN/A

Dividend YieldN/A

Beta2.52

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. Read More…

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:TRLPF

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.aceruspharma.com/

Phone416-679-0771

Debt

Debt-to-Equity Ratio0.64

Current Ratio1.35

Quick Ratio0.90

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.38 million

Price / Sales0.00

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-18,790,000.00

Net Margins-254.66%

Return on Equity-346.72%

Return on Assets-94.54%

Miscellaneous

Employees29

Outstanding Shares258,610,000

Market Cap$23.28 million

Next Earnings DateN/A

OptionableNot Optionable

Receive TRLPF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

Acerus Pharmaceuticals (OTCMKTS:TRLPF) Frequently Asked Questions

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) released its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.01). The specialty pharmaceutical company had revenue of $1.58 million for the quarter. Acerus Pharmaceuticals had a negative return on equity of 346.72% and a negative net margin of 254.66%. View Acerus Pharmaceuticals' Earnings History.

Has Acerus Pharmaceuticals been receiving favorable news coverage?

Media stories about TRLPF stock have trended very negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Acerus Pharmaceuticals.

Who are some of Acerus Pharmaceuticals' key competitors?

Some companies that are related to Acerus Pharmaceuticals include Verastem (VSTM), PhaseBio Pharmaceuticals (PHAS), Inflarx (IFRX), Scpharmaceuticals (SCPH), Oramed Pharmaceuticals (ORMP), vTv Therapeutics (VTVT), Millendo Therapeutics (MLND), ASLAN PHARMACEU/ADR (ASLN), Cumberland Pharmaceuticals (CPIX), Otonomy (OTIC), Neos Therapeutics (NEOS), Synlogic (SYBX), Vaccinex (VCNX), ESSA Pharma (EPIX) and Selecta Biosciences (SELB).

What other stocks do shareholders of Acerus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acerus Pharmaceuticals investors own include Aurora Cannabis (ACBFF), Zynerba Pharmaceuticals (ZYNE), OHR Pharmaceutical (OHRP), Algonquin Power & Utilities (AQN), Nordic American Tanker (NAT), Acerus Pharmaceuticals (ASP), Premier Gold Mines (PG), IBEX Technologies (IBT), Orocobre (ORE) and Astro Japan Property Group (AJA).

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the folowing people:

Ms. Patricia Symmes, Chief Operating Officer
Dr. Nathan Bryson, Chief Scientific Officer
Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
Mr. Edward Gudaitis, Pres , CEO & Director
Mr. Robert M. Motz, Chief Financial Officer

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of $0.00 and generates $7.38 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe.View Additional Information About Acerus Pharmaceuticals.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is http://www.aceruspharma.com/.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]

MarketBeat Community Rating for Acerus Pharmaceuticals (OTCMKTS TRLPF)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		81 (Vote Outperform)
Underperform Votes:		80 (Vote Underperform)
Total Votes:		161

MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe TRLPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRLPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: How to Invest in Stocks with Increasing Dividends